KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Inventory: 2021-2024

Historic Inventory for Novavax (NVAX) over the last 4 years, with Dec 2024 value amounting to $8.7 million.

  • Novavax's Inventory rose 56.41% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year increase of 56.41%. This contributed to the annual value of $8.7 million for FY2024, which is 79.02% down from last year.
  • According to the latest figures from FY2024, Novavax's Inventory is $8.7 million, which was down 79.02% from $41.7 million recorded in FY2023.
  • Over the past 5 years, Novavax's Inventory peaked at $41.7 million during FY2023, and registered a low of $8.7 million during FY2024.
  • For the 3-year period, Novavax's Inventory averaged around $29.0 million, with its median value being $36.7 million (2022).
  • Its Inventory has fluctuated over the past 5 years, first surged by 313.47% in 2022, then slumped by 79.02% in 2024.
  • Over the past 4 years, Novavax's Inventory (Yearly) stood at $8.9 million in 2021, then soared by 313.47% to $36.7 million in 2022, then grew by 13.67% to $41.7 million in 2023, then crashed by 79.02% to $8.7 million in 2024.